Literature DB >> 1668388

Central nervous system binding sites for calcitonin and calcitonin gene-related peptide.

P M Sexton1.   

Abstract

Alternative splicing of the primary RNA transcript of the calcitonin gene leads to the generation of two distinct peptides, calcitonin (CT) and calcitonin gene-related peptide (CGRP). These peptides share only limited sequence homology and generally subserve different biological functions through their own distinct binding sites, which differ in specificity and distribution. Additionally, a binding site with high-affinity binding for both peptides that has a restricted pattern of distribution has been identified. The present article reviews the biochemical and morphological characteristics of centra CT and CGRP binding sites.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1668388     DOI: 10.1007/bf02935550

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  111 in total

1.  Intracerebroventricular administration of calcitonin enhances glucose-stimulated release of insulin.

Authors:  G H Greeley; C W Cooper; Y J Jeng; J C Eldridge; J C Thompson
Journal:  Regul Pept       Date:  1989-03

2.  Evidence for calcitonin receptor heterogeneity: binding studies with nonhelical analogs.

Authors:  H Nakamuta; R C Orlowski; R M Epand
Journal:  Endocrinology       Date:  1990-07       Impact factor: 4.736

3.  Calcitonin as a feeding suppressant: localization of central action to the cerebral III ventricle.

Authors:  C R Plata-Salamán; Y Oomura
Journal:  Physiol Behav       Date:  1987

4.  The analgesic activity of calcitonin and the central serotonergic system.

Authors:  G Clementi; M Amico-Roxas; E Rapisarda; A Caruso; A Prato; S Trombadore; G Priolo; U Scapagnini
Journal:  Eur J Pharmacol       Date:  1985-01-15       Impact factor: 4.432

5.  Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.

Authors:  F Nicoletti; G Clementi; F Patti; P L Canonico; R M Di Giorgio; M Matera; G Pennisi; L Angelucci; U Scapagnini
Journal:  Brain Res       Date:  1982-11-04       Impact factor: 3.252

6.  Cerebroventricular calcitonin gene-related peptide inhibits rat duodenal bicarbonate secretion by release of norepinephrine and vasopressin.

Authors:  H J Lenz; M R Brown
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Further evidence for calcitonin gene duplication: the identification of two different calcitonins in a fish, a reptile and two mammals.

Authors:  R Perez Cano; S I Girgis; I MacIntyre
Journal:  Acta Endocrinol (Copenh)       Date:  1982-06

8.  Effects of calcitonin gene-related peptide on food intake.

Authors:  D D Krahn; B A Gosnell; A S Levine; J E Morley
Journal:  Peptides       Date:  1984 Sep-Oct       Impact factor: 3.750

9.  Calcitonin gene-related peptide receptor in cultured vascular smooth muscle and endothelial cells.

Authors:  Y Hirata; Y Takagi; S Takata; Y Fukuda; H Yoshimi; T Fujita
Journal:  Biochem Biophys Res Commun       Date:  1988-03-30       Impact factor: 3.575

Review 10.  The calcitonin gene peptides: biology and clinical relevance.

Authors:  M Zaidi; B S Moonga; P J Bevis; Z A Bascal; L H Breimer
Journal:  Crit Rev Clin Lab Sci       Date:  1990       Impact factor: 6.250

View more
  15 in total

1.  Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain.

Authors:  A A Mathé; S Gruber; P A Jiménez; E Theodorsson; C Stenfors
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

Review 2.  Salmon calcitonin: a review of current and future therapeutic indications.

Authors:  C H Chesnut; M Azria; S Silverman; M Engelhardt; M Olson; L Mindeholm
Journal:  Osteoporos Int       Date:  2007-12-11       Impact factor: 4.507

Review 3.  CGRP receptor antagonism and migraine.

Authors:  Lars Edvinsson; Tony W Ho
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

4.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.

Authors:  Lars Edvinsson
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 6.  Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications.

Authors:  L Edvinsson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

7.  Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Authors:  Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

Review 8.  Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review.

Authors:  Peer Tfelt-Hansen; Han Le
Journal:  J Headache Pain       Date:  2009-03-28       Impact factor: 7.277

Review 9.  Dural Immune Cells, CGRP, and Migraine.

Authors:  Louis K Balcziak; Andrew F Russo
Journal:  Front Neurol       Date:  2022-03-31       Impact factor: 4.086

10.  Microinjection of calcitonin in midbrain periaqueductal gray attenuates hyperalgesia in a chronic constriction injury rat model.

Authors:  Zongpeng Li; Zong Gao; Shufa Li; Yuanyuan Zhang; Lizhi Xing; Lanju Zhang; Guijie Ma; Xinbo Zhao; Mingtao Shao
Journal:  Iran J Basic Med Sci       Date:  2015-01       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.